Bumper Offer - Urjas oil Just @ Rs. 1
Cyblex MV 80.2 Tablet (15) is a prescription drug, available for use as Tablet. The alternative uses of Cyblex MV 80.2 Tablet (15) have also been explained below.
The right dosage of Cyblex MV 80.2 Tablet (15) depends on the age, gender, and medical history of the patient. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Detailed information has been provided in the dosage section.
The most common side effects of Cyblex MV 80.2 Tablet (15) are Rash, Flatulence, Diarrhoea. Some other side effects of Cyblex MV 80.2 Tablet (15) have been listed ahead. These side effects of Cyblex MV 80.2 Tablet (15) are usually temporary and subside with the completion of treatment. Consult your doctor if these side effects become worse or stay for a longer duration.
In addition, Cyblex MV 80.2 Tablet (15)'s effect is Severe during pregnancy and Severe for lactating mothers. In addition, Cyblex MV 80.2 Tablet (15)'s effects on the liver, heart and kidney are discussed below in the Cyblex MV 80.2 Tablet (15) related warnings section.
Cyblex MV 80.2 Tablet (15) can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Cyblex MV 80.2 Tablet (15) in conditions like Digestive Disorders, Intestinal Obstruction, Allergy. Some other conditions that can be affected by Cyblex MV 80.2 Tablet (15) are listed in the contraindications section below.
Drug interactions for Cyblex MV 80.2 Tablet (15) have been reported in the medical literature. See below for a complete list.
You should also be aware that Cyblex MV 80.2 Tablet (15) is safe while driving, and is addiction.
Cyblex MV 80.2 Tablet (15) is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
Based on research, the following side effects have been observed when Cyblex MV 80.2 Tablet (15) is used -
Severe
Moderate
Mild
Common
Is the use of Cyblex MV 80.2 Tablet (15) safe for pregnant women?
Cyblex Mv has many dangerous side effects in pregnant women. If you are pregnant, do not consume Cyblex Mv without medical advice.
Is the use of Cyblex MV 80.2 Tablet (15) safe during breastfeeding?
Taking Cyblex Mv may lead to serious side effects if you are breastfeeding. Cyblex Mv should not be taken by breastfeeding women unless prescribed by the doctor.
What is the effect of Cyblex MV 80.2 Tablet (15) on the Kidneys?
There can be some harmful effects on your kidneys after taking Cyblex Mv. If you witness any side effects, discontinue its use. Consult your medical practitioner, do as he/she suggests.
What is the effect of Cyblex MV 80.2 Tablet (15) on the Liver?
Cyblex Mv can have moderate side effects on the liver. If you notice any harmful effects then stop taking this drug right away. Consult your doctor before using this medicine again.
What is the effect of Cyblex MV 80.2 Tablet (15) on the Heart?
Side effects of Cyblex Mv rarely affect the heart.
Cyblex MV 80.2 Tablet (15) should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
Mild
If you are suffering from any of the following diseases, you should not take Cyblex MV 80.2 Tablet (15) unless your doctor advises you to do so -
Is this Cyblex MV 80.2 Tablet (15) habit forming or addictive?
Forming a habit of Cyblex MV 80.2 Tablet (15) has not been reported.
Interaction between Food and Cyblex MV 80.2 Tablet (15)
There is no information on the effects of taking Cyblex MV 80.2 Tablet (15) with food, because this topic has not been scientifically researched yet.
Interaction between Alcohol and Cyblex MV 80.2 Tablet (15)
Taking Cyblex MV 80.2 Tablet (15) with alcohol can have severely harmful effects on your health.
This medicine data has been created by -
References
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 277
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Glucophage® (metformin hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 275-276
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 825-826
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 272
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1314-1315
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 272
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1314-1315
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 277
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Glucophage® (metformin hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 275-276
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 825-826
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 277
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Glucophage® (metformin hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 275-276
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 825-826